JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Aptamer-Coated PLGA Nanoparticles Selectively Internalize into Epithelial Ovarian Cancer Cells In Vitro and In Vivo

  • 0Center for Biomedical Engineering and Sciences, University of North Carolina at Charlotte, 9201 University Blvd., Charlotte, NC 28223, USA.
Biomolecules +

|

August 28, 2025

|

August 28, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Researchers developed aptamer-labeled nanoparticles for targeted ovarian cancer therapy. This novel approach enhances drug delivery to cancer cells, reducing proliferation and improving tumor targeting in vivo.

Area Of Science

  • Biomedical Engineering
  • Nanotechnology
  • Oncology

Background

  • Ovarian cancer remains a significant cause of cancer-related deaths in women.
  • Early diagnosis and targeted treatment are crucial for improving patient survival rates.
  • Novel strategies are needed to enhance the efficacy of ovarian cancer therapies.

Purpose Of The Study

  • To develop and evaluate aptamer-RALA01-labeled nanoparticles for targeted delivery to epithelial ovarian cancer (EOC) cells.
  • To assess the ability of these nanoparticles to deliver therapeutic payloads and inhibit EOC cell growth.
  • To investigate the in vivo tumor-targeting capabilities of aptamer-functionalized nanoparticles.

Main Methods

  • Functionalization of PLGA-based nanoparticles with a single-strand DNA aptamer (RLA01) specific for EOC cells.
  • In vitro assessment of cellular uptake in EOC (Caov-3) and non-target (HOSE 6-3) cells via receptor-mediated endocytosis.
  • Evaluation of paclitaxel-loaded nanoparticle efficacy in reducing cell proliferation and inducing apoptosis.
  • Preliminary in vivo studies to assess nanoparticle stability and tumor retention.

Main Results

  • RLA01-labeled nanoparticles significantly enhanced cellular uptake (20-85%) into EOC cells while showing minimal uptake in non-target cells.
  • Paclitaxel-loaded RLA01 nanoparticles effectively inhibited EOC cell proliferation and induced apoptosis.
  • In vivo studies indicated aptamer-mediated nanoparticle retention and tumor homing.

Conclusions

  • Aptamer RLA01-functionalized nanoparticles demonstrate selective targeting and enhanced payload delivery to EOC cells in vitro.
  • This combinatorial approach shows promise for targeted ovarian cancer therapy with potential for improved in vivo efficacy.
  • Aptamer-nanoparticle conjugates represent a viable strategy for direct tumor cell targeting in ovarian malignancies.

Keywords: